- Home
- GLUE vs CTBI Comparison
GLUE vs CTBI Comparison
Compare GLUE & CTBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLUE | CTBI |
|---|---|---|
| Founded | 2019 | 1903 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | GLUE | CTBI |
|---|---|---|
| Price | $13.81 | $77.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $32.00 | ★ $63.00 |
| AVG Volume (30 Days) | ★ 948.5K | 77.5K |
| Earning Date | 05-08-2026 | 04-15-2026 |
| Dividend Yield | N/A | ★ 3.26% |
| EPS Growth | N/A | ★ 17.79 |
| EPS | N/A | ★ 3.14 |
| Revenue | ★ $123,672,000.00 | N/A |
| Revenue This Year | N/A | $14.02 |
| Revenue Next Year | $2.45 | $4.30 |
| P/E Ratio | $72.42 | ★ $24.74 |
| Revenue Growth | ★ 63.54 | N/A |
| 52 Week Low | $6.07 | $50.25 |
| 52 Week High | $25.77 | $79.92 |
Technical Indicators
Market Signals| Indicator | GLUE | CTBI |
|---|---|---|
| Relative Strength Index (RSI) | 37.81 | 57.31 |
| Support Level | N/A | $76.87 |
| Resistance Level | $16.66 | $78.03 |
| Average True Range (ATR) | 0.78 | 1.32 |
| MACD | 0.19 | -0.16 |
| Stochastic Oscillator | 38.90 | 67.90 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About CTBI Community Trust Bancorp Inc.
Community Trust Bancorp Inc is a bank holding company. The Bank owns all the capital stock of one commercial bank and one trust company, serving small and mid-sized communities in eastern, north-eastern, central, and south-central Kentucky, southern West Virginia, and north-eastern Tennessee. Through its subsidiaries, the Bank is engaged in commercial and personal banking and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals, and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes; and providing funds transfer services. The company operates in one reportable segment: community banking services.